Study of association between molecular marker expression on tumor and immunocompetent cells and sensitivity to adjuvant and neoadjuvant therapy of bladder cancer
| Autor: | I. N. Zaborskiy, S. A. Ivanov, T. Yu. Mushkarina, O. B. Karyakin, E. G. Kuzmina, K. N. Safiullin, V. S. Chaykov, A. V. Troyanov, I. O. Dementiev, M. R. Kasymov, G. A. Demyashkin |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Urology Immune checkpoint inhibitors medicine.medical_treatment chemotherapy pd-1 receptor morphological specification pd-l2 03 medical and health sciences 0302 clinical medicine pd-l1 Internal medicine PD-L1 medicine Effective treatment Radiology Nuclear Medicine and imaging Disease prognosis Cisplatin Chemotherapy Bladder cancer biology business.industry Immunotherapy medicine.disease 030104 developmental biology muscle-invasive bladder cancer Nephrology 030220 oncology & carcinogenesis biology.protein Medicine Surgery immunotherapy business medicine.drug |
| Zdroj: | Onkourologiâ, Vol 15, Iss 2, Pp 100-106 (2019) |
| ISSN: | 1996-1812 1726-9776 |
| Popis: | Use of immunotherapy in treatment of muscle-invasive bladder cancer remains the most promising method in case of impossibility of chemotherapy with cisplatin or progression during cisplatin treatment. This approach is the method of choice and can prolong patient’s life. In particular, use of checkpoint inhibitors allows to obtain effective treatment of bladder cancer. However, to prescribe immunotherapeutic medication, patient must have point of application for these drugs. Individualized approach will allow to increase treatment effectiveness and disease prognosis while maximally improving the quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|